SCHEMBL30278346

SCHEMBL30278346

CC(CC1CCCCC1)N(Cc1cccc2ccn(CCO)c12)C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.35
METAP1 P53582 1/20 0.35
NPY5R Q15761 1/20 0.33
HTR2C P28335 5/20 0.33
SLC6A4 P31645 5/20 0.33
BCHE P06276 7/20 0.32
ACHE P22303 6/20 0.32
NPSR1 Q6W5P4 3/20 0.32
ACKR3 P25106 1/20 0.32
REN P00797 1/20 0.31
HTR2A P28223 1/20 0.31
KDM4E B2RXH2 1/20 0.30
APAF1 O14727 1/20 0.30
TSHR P16473 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30278292 0.89 NPY5R (0.37) METAP2METAP1NPY5RHTR2CSLC6A4
SCHEMBL23005058 0.88 METAP2 (0.38) METAP2METAP1NPY5RHTR2CNPSR1
SCHEMBL23004827 0.88 NPY5R (0.34) METAP2METAP1NPY5RHTR2CSLC6A4
SCHEMBL30278360 0.78 BCHE (0.41) METAP2METAP1NPY5RBCHEACHE
SCHEMBL23005049 0.77 NPY5R (0.40) METAP2METAP1NPY5RNPSR1KDM4E
SCHEMBL30278336 0.76 NPY5R (0.41) METAP2METAP1NPY5RHTR2CSLC6A4
SCHEMBL23022839 0.75 ATM (0.47) NPY5RHTR2CSLC6A4BCHEACHE
SCHEMBL23005059 0.74 CTSK (0.44) TSHRHSD17B10
SCHEMBL23023033 0.73 HTR2A (0.39) METAP2METAP1NPY5RHTR2CSLC6A4
SCHEMBL30278355 0.73 NPY5R (0.39) METAP2METAP1NPY5RHTR2CSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230102879-A1 TRNA SYNTHETASE INHIBITORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2023-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230102879-A1 TRNA SYNTHETASE INHIBITORS TRMT1, AARS1, GARS1 METAP2 819/4885METAP1 619/4885NPY5R 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.